IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share

Core Insights - Iradimed Corporation reported record revenue of $22.7 million for Q4 2025, marking a 17% increase year-over-year and surpassing previous guidance [2][7] - The company achieved a net income of $6.4 million for Q4 2025, a 25% increase compared to the same period in 2024 [7][10] - Iradimed plans to roll out its next-generation 3870 MRI-compatible IV infusion pump in Q1 2026, with significant revenue contributions expected in the second half of the year [2][4] Financial Performance - For Q4 2025, total revenue was $22.7 million, up from $19.4 million in Q4 2024, representing a 17% increase [7][12] - The company reported a GAAP diluted EPS of $0.50 for Q4 2025, a 25% increase from $0.40 in Q4 2024 [8][10] - For the full year 2025, revenue reached $83.8 million, a 14% increase from $73.2 million in 2024 [10][11] Guidance and Dividends - For the full year 2026, Iradimed expects revenue between $91.0 million and $96.0 million, with GAAP diluted EPS projected between $1.90 and $2.05 [4][17] - The company declared a quarterly cash dividend of $0.20 per share, up from $0.17, reflecting confidence in future business outlook [3][5] Product Development and Market Position - Iradimed is a leader in MRI-compatible medical devices, providing non-magnetic IV infusion pump systems and patient vital signs monitoring systems [1][27] - The company’s patented MRidium® MRI-compatible IV infusion pump system is designed to safely deliver fluids during MRI procedures, addressing safety concerns associated with traditional pumps [28] - The 3880 MRI-compatible patient vital signs monitoring system is engineered to operate in high magnetic fields, enhancing patient safety during MRI scans [29]